Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial.
Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial.
复制标题
贯叶金丝桃（圣约翰草）治疗儿童和青少年注意力缺陷/多动障碍：一项随机对照试验。
DOI：
10.1001/jama.299.22.2633
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
McClellan,Jon
中科院分区：
文献类型：
--
作者：
Weber,Wendy;VanderStoep,Ann;McCarty,RachelleL;Weiss,NoelS;Biederman,Joseph;McClellan,Jon
兴奋剂药物可以有效地治疗60-70%的注意缺陷多动障碍青少年。然而，许多父母寻求替代疗法，贯叶连翘是使用的三大植物之一。目的观察贯叶连翘治疗儿童注意缺陷多动障碍的疗效和安全性。设计、设置和参与者：2005年3月至2006年8月在Bastyr大学对54名儿童进行了随机双盲安慰剂对照试验。通过结构化访谈，对6-17岁符合DSM-IV注意缺陷多动障碍诊断标准的儿童进行志愿者样本。试验期间不允许使用其他ADHD药物。安慰剂组1例患者因不良事件退出研究。干预参与者被随机接受300毫克贯叶连翘或匹配的安慰剂，每天三次，持续八周。主要结果测量ADHD评定量表-IV（0 - 54），临床总体印象量表的改善和严重程度（0 - 7），结果治疗组和安慰剂组ADHD量表IV评分从基线到第8周的变化无显著性差异（注意力不集中改善2.6分，金丝桃（95% CI-4.6至-0.6）对比安慰剂3.2分（95% CI −5.7至−0.8），p = 0.68;多动改善1.8分金丝桃（95% CI −3.7至0.04）与2.0分安慰剂（95% CI −4.1至0.1），p = 0.89）。两组间符合临床总体印象改善量表改善标准（评分为2分或更低）的受试者比例也无显著差异（金丝桃44.4%（95% CI 25.5至64.7）vs.安慰剂51.9%（95% CI 31.9至71.3），p = 0.59）。在研究期间，两组间发生不良反应的受试者人数无差异（金丝桃40.7%（95% CI 22.4至61.2）vs.安慰剂44.4%（95% CI 25.5至64.7），p = 0.78）。结论在这项研究中，使用贯叶连翘治疗注意缺陷多动障碍超过8周的过程中没有改善症状。
Context Stimulant medication can effectively treat 60–70% of youth with attention deficit hyperactivity disorder. Yet, many parents seek out alternative therapies, and Hypericum perforatum is one of the top three botanicals used. Objective To determine the efficacy and safety of Hypericum perforatum for the treatment of attention deficit hyperactivity disorder in children. Design, Setting, and Participants A randomized double-blind placebo-controlled trial of 54 children was conducted between March 2005 and August 2006 at Bastyr University. A volunteer sample of children aged 6–17 years met DSM-IV criteria for attention deficit hyperactivity disorder by structured interview. Other medications for ADHD were not allowed during the trial. One patient in the placebo group withdrew due to an adverse event. Intervention Participants were randomized to receive 300 mg of Hypericum perforatum or a matched placebo three times daily for eight weeks. Main Outcome Measures ADHD Rating Scale-IV (0 to 54), Clinical Global Impression scales for Improvement and Severity (0 to 7), and adverse events Results No significant difference in the change of ADHD Rating Scale-IV score from baseline to week 8 was found between treatment and placebo groups (inattention improved 2.6 points Hypericum (95% CI −4.6 to −0.6) vs. 3.2 points placebo (95% CI −5.7 to −0.8), p = 0.68; hyperactivity improved 1.8 points Hypericum (95% CI −3.7 to 0.04) vs. 2.0 points placebo (95% CI −4.1 to 0.1), p = 0.89). There was also no significant difference between groups in the proportion of participants who met criteria for improvement (score of 2 or less) on the Clinical Global Impression Improvement Scale (Hypericum 44.4% (95% CI 25.5 to 64.7) vs. placebo 51.9% (95% CI 31.9 to 71.3), p = 0.59). No difference between groups was found in the number of participants who experienced adverse effects during the study period (Hypericum 40.7% (95% CI 22.4 to 61.2) vs. placebo 44.4% (95% CI 25.5 to 64.7), p = 0.78). Conclusions In this study, use of Hypericum perforatum for the treatment of attention deficit hyperactivity disorder over the course of eight weeks did not improve symptoms.